ArticleNature communications2024
HIF1α-regulated glycolysis promotes activation-induced cell death and IFN-γ induction in hypoxic T cells.
Abstract read
In one paragraph
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed.
- Sequential axitinib and survivin vaccination unlock curative PD-1 immunotherapy in renal carcinoma.Oncoimmunology · 2026Article
- SPRED2 Negatively Regulates CD8Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- HDCA suppresses exosomal lncRNA MSTRG171708 release to inhibit Treg-mediated immunometabolism in hepatocellular carcinoma.Molecular biomedicine · 2026Article
- Targeting PKM2 Enhances the Anti-Tumor Function of CD8International journal of molecular sciences · 2026Article
- Forkhead Box O1 Promotes Osteogenesis of Periodontal Ligament Stem Cells Via Glycolysis-Related Metabolic Reprogramming.International dental journal · 2026Article
- Nanomedicine targeting ECM stiffness: restoring mechanical homeostasis for cancer immunotherapy.Materials today. Bio · 2026Review
- HIF-1α in CD4Journal of pharmaceutical analysis · 2026Article
- Lactate Uptake by MCT4 Facilitates Stability and Suppressive Function of Tumor-Infiltrating Regulatory T Cells by Promoting Foxp3 Lactylation.International journal of molecular sciences · 2026Article
- Glucose metabolic reprogramming as a driver of immunosuppression in the tumour microenvironment.Clinical and translational medicine · 2026Review
- The hypoxia-inflammation cycle as a key mechanism of smoldering inflammation and progression in multiple sclerosis.Acta neuropathologica · 2026Review
- Functional segregation of HIF-1α and AhR controls NK cell responsiveness under hypoxia.iScience · 2026Article
- Research progress on the mechanisms of EB virus reshaping the immune microenvironment in nasopharyngeal carcinoma.Clinical and experimental medicine · 2026Review
- YBX1 promotes angiogenesis after myocardial infarction by stabilizing HIF1α mRNA via miScience · 2026Article
- Targeting metabolic reprogramming to enhance adoptive immunotherapy: emerging mechanisms and translational perspectives.Journal of translational medicine · 2026Review
- PD-1 protects expanding human T cells from premature restimulation-induced cell death by modulating TCR and CD28 signaling.Cell death & disease · 2026Article
- [Impact of HIF-1α-expressing Cellular Subpopulations on Lymph Node Metastasis and Postoperative Recurrence in Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Article
- Regulators of CD8Nature reviews. Immunology · 2026Review
- Roles of the Altitude-Adapted Immune Microenvironment in Pulmonary Vascular Remodeling in High-Altitude Pulmonary Hypertension: A Review.Medical science monitor : international medical journal of experimental and clinical research · 2026Review
- The IDO1/AhR-HIF-1α metabolic axis: ARNT competition as a central antagonistic switch in autoimmune pathogenesis.Frontiers in immunology · 2026Review
- Tumor-immune metabolic tug-of-war: from immune escape to targeting metabolic rewiring in cancer therapy.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
- Update of
Authors and funding
14 authors.
Hongxing ShenDepartment of Radiation Oncology, Heersink School of Medicine, University of Alabama at Birmingham (UAB-SOM), Birmingham, AL, USA.ORCID 0000-0001-7400-6809
Oluwagbemiga A OjoDepartment of Radiation Oncology, Heersink School of Medicine, University of Alabama at Birmingham (UAB-SOM), Birmingham, AL, USA.ORCID 0000-0002-0086-6694
Haitao DingDepartment of Radiation Oncology, Heersink School of Medicine, University of Alabama at Birmingham (UAB-SOM), Birmingham, AL, USA.ORCID 0009-0009-1314-6002
Logan J MullenGenomics Core Laboratory, Institute of Arctic Biology, University of Alaska Fairbanks, Fairbanks, Alaska, USA.
Chuan XingDepartment of Radiation Oncology, Heersink School of Medicine, University of Alabama at Birmingham (UAB-SOM), Birmingham, AL, USA.
M Iqbal HossainDepartment of Pharmacology and Toxicology, UAB-SOM, Birmingham, AL, USA.
Abdelrahman YassinDepartment of Radiation Oncology, Heersink School of Medicine, University of Alabama at Birmingham (UAB-SOM), Birmingham, AL, USA.
Vivian Y ShiDepartment of Radiation Oncology, Heersink School of Medicine, University of Alabama at Birmingham (UAB-SOM), Birmingham, AL, USA.
Zach LewisDepartment of Radiation Oncology, Heersink School of Medicine, University of Alabama at Birmingham (UAB-SOM), Birmingham, AL, USA.ORCID 0009-0009-2523-1677
Ewa PodgorskaDepartment of Radiation Oncology, Heersink School of Medicine, University of Alabama at Birmingham (UAB-SOM), Birmingham, AL, USA.ORCID 0000-0002-1550-0871
Shaida A AndrabiDepartment of Pharmacology and Toxicology, UAB-SOM, Birmingham, AL, USA.
Maciek R AntoniewiczDepartment of Chemical Engineering, University of Michigan, Ann Arbor, MI, USA.
James A BonnerDepartment of Radiation Oncology, Heersink School of Medicine, University of Alabama at Birmingham (UAB-SOM), Birmingham, AL, USA.ORCID 0000-0002-8413-3788
Lewis Zhichang ShiDepartment of Radiation Oncology, Heersink School of Medicine, University of Alabama at Birmingham (UAB-SOM), Birmingham, AL, USA. Lewisshi@uabmc.edu.ORCID 0000-0002-5351-8730
Funding
XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Omer Jamy · 1985 to 2026
$165.9MT cell-intrinsic metabolic control of radiotherapyR01CA279849 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Lewis Z. Shi · 2024 to 2026
$1.2MOvercoming Tumor-Intrinsic Therapeutic Resistance to ImmunotherapiesR21CA259721 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SHI, LEWIS ZHICHANG · 2022 to 2023
$378kTargeting metabolic checkpoints in the tumor microenvironment to boost efficacy of anti-CTLA-4R21CA230475 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SHI, LEWIS ZHICHANG · 2019 to 2020
$355kCancer Research Institute (CRI) CRI4342NCI NIH HHS P30 CA013148NCI NIH HHS R01 CA279849NCI NIH HHS R21 CA230475NCI NIH HHS R21 CA259721UAB | School of Medicine, University of Alabama at Birmingham (UAB School of Medicine) O'Neal Invests Pre-R01 AwardU.S. Department of Defense (United States Department of Defense) ME210108U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) 1R01CA279849-01A1U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) 1R21CA230475-01A1U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) 1R21CA259721-01A1V Foundation for Cancer Research (V Foundation) V2018-023
Abstract
Hypoxia is a common feature in various pathophysiological contexts, including tumor microenvironment, and IFN-γ is instrumental for anti-tumor immunity. HIF1α has long been known as a primary regulator of cellular adaptive responses to hypoxia, but its role in IFN-γ induction in hypoxic T cells is unknown. Here, we show that the HIF1α-glycolysis axis controls IFN-γ induction in both human and mouse T cells, activated under hypoxia. Specific deletion of HIF1α in T cells (Hif1α
Indexed as
GlycolysisHypoxia-Inducible Factor 1, alpha SubunitInterferon-gammaT-LymphocytesAnimalsCell DeathCell HypoxiaCell Line, TumorHumansImmune Checkpoint InhibitorsLymphocyte ActivationMiceMice, Inbred C57BLMice, KnockoutTumor MicroenvironmentVon Hippel-Lindau Tumor Suppressor ProteinHIF1A protein, humanHif1a protein, mouseHypoxia-Inducible Factor 1, alpha SubunitImmune Checkpoint InhibitorsInterferon-gammaVon Hippel-Lindau Tumor Suppressor Protein
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.